Polymeric Nanoparticles with ROS‐Responsive Prodrug and Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon Cancer
The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poo...
Saved in:
| Published in | Advanced science Vol. 7; no. 20; pp. 2001853 - n/a |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Germany
John Wiley & Sons, Inc
01.10.2020
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy.
The platinum nanozyme (PtNP) loaded reactive oxygen species‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) which could achieve the “on‐demand” release of CPT and relieve hypoxia to enhance photodynamic therapy efficiency, exhibits desirable long circulation and effectively inhibits tumor proliferation and growth in vitro and in vivo, has great promising potential in chemophotodynamic synergistic cancer therapy. |
|---|---|
| AbstractList | The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. Abstract The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H 2 O 2 ) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia-associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)-responsive prodrug nanoparticle (CPT-TK-HPPH/Pt NP) is created to overcome these limitations. The ROS-responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer-2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH). The PtNP in CPT-TK-HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H O ) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on-demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT-TK-HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT-TK-HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT-TK-HPPH/Pt NP, with its excellent ROS-responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. Abstract The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H 2 O 2 ) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. The platinum nanozyme (PtNP) loaded reactive oxygen species‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) which could achieve the “on‐demand” release of CPT and relieve hypoxia to enhance photodynamic therapy efficiency, exhibits desirable long circulation and effectively inhibits tumor proliferation and growth in vitro and in vivo, has great promising potential in chemophotodynamic synergistic cancer therapy. The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia-associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)-responsive prodrug nanoparticle (CPT-TK-HPPH/Pt NP) is created to overcome these limitations. The ROS-responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer-2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH). The PtNP in CPT-TK-HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on-demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT-TK-HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT-TK-HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT-TK-HPPH/Pt NP, with its excellent ROS-responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy.The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia-associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)-responsive prodrug nanoparticle (CPT-TK-HPPH/Pt NP) is created to overcome these limitations. The ROS-responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer-2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH). The PtNP in CPT-TK-HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on-demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT-TK-HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT-TK-HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT-TK-HPPH/Pt NP, with its excellent ROS-responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and photodynamic synergistic therapy are impeded by uncontrolled chemotherapeutics release behavior, targeting deficiencies, and hypoxia‐associated poor PDT efficacy in solid tumors. Here, a platinum nanozyme (PtNP) loaded reactive oxygen species (ROS)‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) is created to overcome these limitations. The ROS‐responsive prodrug consists of a thioketal bond linked with camptothecin (CPT) and photosensitizer‐2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH). The PtNP in CPT‐TK‐HPPH/Pt NP can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into oxygen to relieve hypoxia. The production of oxygen can satisfy the consumption of HPPH under 660 nm laser irradiation to attain the on‐demand release of CPT and ensure enhanced photodynamic therapy. As a tumor diagnosis agent, the results of photoacoustic imaging and fluorescence imaging for CPT‐TK‐HPPH/Pt NP exhibit desirable long circulation and enhanced in vivo targeting. CPT‐TK‐HPPH/Pt NPs effectively inhibit tumor proliferation and growth in vitro and in vivo. CPT‐TK‐HPPH/Pt NP, with its excellent ROS‐responsive drug release behavior and enhanced PDT efficiency can serve as a new cancer theranostic agent, and will further promote the research of chemophotodynamic synergistic cancer therapy. The platinum nanozyme (PtNP) loaded reactive oxygen species‐responsive prodrug nanoparticle (CPT‐TK‐HPPH/Pt NP) which could achieve the “on‐demand” release of CPT and relieve hypoxia to enhance photodynamic therapy efficiency, exhibits desirable long circulation and effectively inhibits tumor proliferation and growth in vitro and in vivo, has great promising potential in chemophotodynamic synergistic cancer therapy. |
| Author | Yang, Chengli Hao, Ying Yu, Yongyang Han, Ruxia Li, Yang Hu, Danrong Qian, Zhiyong Chen, Yuwen He, Xinlong |
| AuthorAffiliation | 1 State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University, and Collaborative Innovation Center of Biotherapy Chengdu 610041 P. R. China 2 Department of Gastrointestinal Surgery West China Hospital Sichuan University Chengdu 610041 P. R. China |
| AuthorAffiliation_xml | – name: 2 Department of Gastrointestinal Surgery West China Hospital Sichuan University Chengdu 610041 P. R. China – name: 1 State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University, and Collaborative Innovation Center of Biotherapy Chengdu 610041 P. R. China |
| Author_xml | – sequence: 1 givenname: Ying surname: Hao fullname: Hao, Ying organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 2 givenname: Yuwen surname: Chen fullname: Chen, Yuwen organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 3 givenname: Xinlong surname: He fullname: He, Xinlong organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 4 givenname: Yongyang surname: Yu fullname: Yu, Yongyang organization: Sichuan University – sequence: 5 givenname: Ruxia surname: Han fullname: Han, Ruxia organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 6 givenname: Yang surname: Li fullname: Li, Yang organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 7 givenname: Chengli surname: Yang fullname: Yang, Chengli organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 8 givenname: Danrong surname: Hu fullname: Hu, Danrong organization: Sichuan University, and Collaborative Innovation Center of Biotherapy – sequence: 9 givenname: Zhiyong orcidid: 0000-0003-2992-6424 surname: Qian fullname: Qian, Zhiyong email: zhiyongqian@scu.edu.cn organization: Sichuan University, and Collaborative Innovation Center of Biotherapy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33101874$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstu1DAUhiNUREvpliWyxIbNDHZsJ_YGqRoKVKroqC1sLceXSUaJHexkqmGFeAKekSfBc2HUsmFly_7O53Os_3l25LwzWfYSwSmCMH8r9SpOc5hDiBjFT7KTHHE2wYyQowf74-wsxiVMEMUlQexZdowxSiUlOcl-zn277kxoFPgsne9lGBrVmgjum6EGN9e3v3_8ujGx9y42KwPmweswLoB0GsxbOTRu7LaF35MEWB_AhaulU0aDWW0639d-8HrtZJceuKtNkP0aeAtmvvUOzDZkeJE9tbKN5my_nmZfPlzczT5Nrq4_Xs7OryaKlgRPeAFLUmpOjeFcV5WWCGErISq0lczmmhdFwQpCrLRKVrCiyvBSUVXwsqogwqfZ5c6rvVyKPjSdDGvhZSO2Bz4sxH56oRljUjGFc0VJVWBGCYK65DZPq7E6ud7tXP1YdUYr44Yg20fSxzeuqcXCr0RJS8a3zbzZC4L_Npo4iK6JyrStdMaPUeSEEoIQ5Cyhr_9Bl34MLn3VhspZUVIIEzXdUSr4GIOxh2YQFJu0iE1axCEtqeDVwxEO-N9sJIDsgPumNev_6MT5-6-3OcQY_wFQ_tAp |
| CitedBy_id | crossref_primary_10_3390_ijms232415656 crossref_primary_10_1039_D1QM00295C crossref_primary_10_1039_D4BM00415A crossref_primary_10_1002_wnan_1942 crossref_primary_10_1016_j_rechem_2023_101167 crossref_primary_10_1016_j_actbio_2021_08_015 crossref_primary_10_1186_s12951_024_02431_6 crossref_primary_10_1002_anie_202319966 crossref_primary_10_1002_adom_202202040 crossref_primary_10_1016_j_heliyon_2024_e33637 crossref_primary_10_1021_acsmaterialslett_3c00790 crossref_primary_10_1186_s12951_021_01001_4 crossref_primary_10_1515_mr_2022_0048 crossref_primary_10_1016_j_nano_2022_102549 crossref_primary_10_1002_adhm_202302940 crossref_primary_10_1039_D3TB02288A crossref_primary_10_1016_j_ajps_2022_01_002 crossref_primary_10_1016_j_cej_2022_141186 crossref_primary_10_1016_j_mtbio_2023_100663 crossref_primary_10_3389_fbioe_2023_1294074 crossref_primary_10_1002_anie_202301232 crossref_primary_10_1002_mco2_187 crossref_primary_10_1021_acsami_2c06721 crossref_primary_10_1021_acs_analchem_1c02625 crossref_primary_10_1021_acsnano_1c09959 crossref_primary_10_3389_fimmu_2023_1238827 crossref_primary_10_1002_smtd_202300945 crossref_primary_10_1016_j_ntm_2024_100032 crossref_primary_10_1021_acs_molpharmaceut_2c00550 crossref_primary_10_1039_D2TB02776C crossref_primary_10_1021_acs_jmedchem_4c00249 crossref_primary_10_1039_D3NR04147F crossref_primary_10_3390_molecules28165955 crossref_primary_10_1016_j_biopha_2023_115348 crossref_primary_10_1002_adhm_202300012 crossref_primary_10_1002_ange_202116807 crossref_primary_10_1021_acsami_1c06818 crossref_primary_10_1002_smll_202107656 crossref_primary_10_3389_fphar_2024_1325544 crossref_primary_10_1016_j_nantod_2022_101376 crossref_primary_10_1039_D3QI00376K crossref_primary_10_1039_D3NR01735D crossref_primary_10_2147_IJN_S388342 crossref_primary_10_1166_jbn_2021_3151 crossref_primary_10_3389_fonc_2022_958221 crossref_primary_10_1002_advs_202101454 crossref_primary_10_1039_D2BM02110B crossref_primary_10_1016_j_ccr_2023_215482 crossref_primary_10_1016_j_ijbiomac_2024_130960 crossref_primary_10_3390_chemosensors11070397 crossref_primary_10_1088_1748_605X_ad0b23 crossref_primary_10_2217_nnm_2020_0424 crossref_primary_10_3390_ma14226812 crossref_primary_10_1016_j_jcis_2022_10_003 crossref_primary_10_3390_ijms23126688 crossref_primary_10_1002_EXP_20230027 crossref_primary_10_1021_acs_nanolett_2c01131 crossref_primary_10_1039_D1BM00317H crossref_primary_10_3389_fchem_2022_844426 crossref_primary_10_3389_fchem_2022_1092747 crossref_primary_10_1002_adfm_202206300 crossref_primary_10_1016_j_cej_2023_146450 crossref_primary_10_1002_admi_202002200 crossref_primary_10_1039_D2CC06212G crossref_primary_10_1016_j_apsb_2022_06_001 crossref_primary_10_1109_JSEN_2022_3191291 crossref_primary_10_3390_ijms232012624 crossref_primary_10_1016_j_cej_2023_147932 crossref_primary_10_1039_D2NR00436D crossref_primary_10_1177_15330338231191493 crossref_primary_10_1016_j_ejmech_2022_115084 crossref_primary_10_3389_fbioe_2022_916952 crossref_primary_10_3390_ijms242417404 crossref_primary_10_1016_j_nantod_2023_101816 crossref_primary_10_1002_smll_202310876 crossref_primary_10_1016_j_biomaterials_2021_121193 crossref_primary_10_1186_s12645_023_00198_3 crossref_primary_10_1002_advs_202301985 crossref_primary_10_1016_j_actbio_2021_02_036 crossref_primary_10_1039_D3NR01050C crossref_primary_10_1002_adhm_202200268 crossref_primary_10_1039_D2NR05276H crossref_primary_10_1002_smll_202203400 crossref_primary_10_1016_j_ccr_2022_214495 crossref_primary_10_1016_j_jcis_2023_05_003 crossref_primary_10_1016_j_nano_2022_102581 crossref_primary_10_1016_j_trac_2020_116080 crossref_primary_10_1002_anie_202116807 crossref_primary_10_1021_acsami_3c06189 crossref_primary_10_1016_j_addr_2022_114344 crossref_primary_10_1016_j_ccr_2022_214808 crossref_primary_10_1039_D2CS00518B crossref_primary_10_1016_j_ccr_2022_214760 crossref_primary_10_1002_advs_202103444 crossref_primary_10_1166_mex_2024_2638 crossref_primary_10_1002_admi_202201823 crossref_primary_10_1039_D1TB01771C crossref_primary_10_1002_mabi_202200105 crossref_primary_10_1021_acsnano_1c08544 crossref_primary_10_1021_acsami_2c02725 crossref_primary_10_1021_acsami_2c09071 crossref_primary_10_1039_D2QM00960A crossref_primary_10_1039_D1MH02042K crossref_primary_10_1021_acsnano_3c06019 crossref_primary_10_3390_pharmaceutics14112280 crossref_primary_10_1021_acsami_2c16199 crossref_primary_10_1002_adfm_202103591 crossref_primary_10_1021_acsami_3c16022 crossref_primary_10_1016_j_bioactmat_2022_03_022 crossref_primary_10_3390_life13020305 crossref_primary_10_1002_cnma_202100532 crossref_primary_10_1002_ange_202301232 crossref_primary_10_1007_s00018_023_04694_y crossref_primary_10_1039_D3NR02345A crossref_primary_10_1002_adfm_202404900 crossref_primary_10_1002_slct_202100480 crossref_primary_10_1016_j_cej_2023_141485 crossref_primary_10_1016_j_actbio_2023_12_012 crossref_primary_10_1155_2021_9980127 crossref_primary_10_1186_s12951_021_00877_6 crossref_primary_10_1002_marc_202100111 crossref_primary_10_3390_pharmaceutics14071522 crossref_primary_10_3390_cancers14184462 crossref_primary_10_1021_acs_macromol_3c01895 crossref_primary_10_1016_j_biomaterials_2022_121975 crossref_primary_10_1016_j_jddst_2024_105827 crossref_primary_10_1016_j_addr_2023_115137 crossref_primary_10_3390_pharmaceutics14010120 crossref_primary_10_1016_j_actbio_2021_03_045 crossref_primary_10_1016_j_onano_2022_100100 crossref_primary_10_1016_j_matdes_2022_111430 crossref_primary_10_1016_j_cej_2023_142961 crossref_primary_10_1016_j_biomaterials_2024_122585 crossref_primary_10_1002_ange_202319966 crossref_primary_10_3389_fonc_2022_934928 crossref_primary_10_1016_j_cej_2022_137110 crossref_primary_10_1002_slct_202200850 crossref_primary_10_1002_advs_202200999 crossref_primary_10_1002_mog2_67 crossref_primary_10_1016_j_jddst_2024_105713 crossref_primary_10_1016_j_ejmech_2022_114749 |
| Cites_doi | 10.1002/viw2.6 10.1016/j.cclet.2019.04.052 10.1166/jbn.2019.2667 10.1021/acsami.7b17323 10.1016/j.jconrel.2018.12.042 10.1038/s41467-018-04318-1 10.1016/j.biomaterials.2020.119827 10.1002/smll.201803602 10.1039/C9TB00847K 10.1002/adtp.201900059 10.1016/j.actbio.2019.05.008 10.1016/j.biomaterials.2018.12.032 10.1039/C8CS00304A 10.1016/j.cclet.2018.06.009 10.1016/j.biomaterials.2018.04.015 10.1002/adma.201806803 10.1016/j.biomaterials.2018.12.021 10.1021/acsnano.9b02096 10.1021/acsnano.9b02477 10.1002/anie.201805138 10.1002/adfm.201805764 10.1002/adtp.201800008 10.1021/acsbiomaterials.7b00523 10.1002/adfm.201808462 10.1002/adfm.201706310 10.1166/mex.2019.1552 10.1016/j.nantod.2019.03.007 10.1021/acsnano.8b08346 10.1021/acsami.7b03604 10.1002/anie.201801984 10.1002/adfm.201806708 10.1166/jbn.2019.2821 10.3322/caac.21565 10.1016/j.bioactmat.2020.04.002 10.1002/advs.201901690 10.1021/acsami.0c00650 10.1039/C8NR07679K 10.7150/thno.22989 10.1016/j.biomaterials.2019.04.029 10.1021/acs.chemmater.9b00439 10.1039/C5RA26563K |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. Published by Wiley‐VCH GmbH 2020 The Authors. Published by Wiley‐VCH GmbH. 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. Published by Wiley‐VCH GmbH – notice: 2020 The Authors. Published by Wiley‐VCH GmbH. – notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P WIN NPM AAYXX CITATION 3V. 7XB 88I 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH HCIFZ M2O M2P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1002/advs.202001853 |
| DatabaseName | Wiley-Blackwell Titles (Open access) Wiley Free Archive PubMed CrossRef ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest research library ProQuest Science Journals Research Library (Corporate) Publicly Available Content Database (ProQuest Open Access資料庫) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Science Journals (Alumni Edition) ProQuest Central Student ProQuest Central Basic ProQuest Central Essentials ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley_OA刊 url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2198-3844 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_d888ac8c32c54b6385410d79f2410efd 10_1002_advs_202001853 33101874 ADVS2033 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University funderid: Z2018B06 – fundername: National Natural Science Foundation of China funderid: 31930067; 31525009; 31771096 – fundername: West China Precision Medicine Industrial Technology Institutes funderid: 2018‐CY02‐00058‐GX – fundername: 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University funderid: ZYGD18002 – fundername: The Postdoctoral Innovation Talents Support Program funderid: BX20180207 – fundername: China Postdoctoral Science Foundation funderid: 2019M653410 – fundername: Post‐Doctor Research Project, West China Hospital, Sichuan University funderid: 2018HXBH043 – fundername: National Key Research and Development Program of China funderid: 2017YFC1103502 – fundername: 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University grantid: ZYGD18002 – fundername: ; grantid: 31930067; 31525009; 31771096 – fundername: ; grantid: 2017YFC1103502 – fundername: West China Precision Medicine Industrial Technology Institutes grantid: 2018‐CY02‐00058‐GX – fundername: The Postdoctoral Innovation Talents Support Program grantid: BX20180207 – fundername: National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University grantid: Z2018B06 – fundername: ; grantid: 2019M653410 – fundername: Post‐Doctor Research Project, West China Hospital, Sichuan University grantid: 2018HXBH043 |
| GroupedDBID | 0R~ 1OC 24P 53G 5VS 88I 8G5 AAFWJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACGFS ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AFPKN AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU AZQEC BCNDV BENPR BPHCQ BRXPI CCPQU DWQXO EBS GNUQQ GODZA GROUPED_DOAJ GUQSH HCIFZ HYE IAO KQ8 M2O M2P O9- OK1 PIMPY PQQKQ PROAC ROL RPM WIN EJD ITC NPM AAYXX CITATION 3V. 7XB 8FK MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c5743-960747d95ee99dbbda113fa016dfa8f2d96668644fafcab0b5ce97c5c697bb013 |
| IEDL.DBID | RPM |
| ISSN | 2198-3844 |
| IngestDate | Tue Oct 22 15:10:52 EDT 2024 Tue Sep 17 21:28:31 EDT 2024 Sat Aug 03 16:30:49 EDT 2024 Thu Oct 10 17:33:11 EDT 2024 Thu Sep 26 16:47:38 EDT 2024 Wed Oct 23 09:50:23 EDT 2024 Sat Aug 24 01:04:36 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Keywords | ROS‐responsive prodrugs polymeric nanoparticles chemophotodynamic therapy colon cancer platinum nanozymes |
| Language | English |
| License | Attribution 2020 The Authors. Published by Wiley‐VCH GmbH. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5743-960747d95ee99dbbda113fa016dfa8f2d96668644fafcab0b5ce97c5c697bb013 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2992-6424 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578901/ |
| PMID | 33101874 |
| PQID | 2452867500 |
| PQPubID | 4365299 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d888ac8c32c54b6385410d79f2410efd pubmedcentral_primary_oai_pubmedcentral_nih_gov_7578901 proquest_miscellaneous_2454411098 proquest_journals_2452867500 crossref_primary_10_1002_advs_202001853 pubmed_primary_33101874 wiley_primary_10_1002_advs_202001853_ADVS2033 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-01 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany – name: Weinheim – name: Hoboken |
| PublicationTitle | Advanced science |
| PublicationTitleAlternate | Adv Sci (Weinh) |
| PublicationYear | 2020 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2020 2020; 237 1 2019 2017; 92 4 2016; 6 2019; 9 2020; 5 2018; 28 2018; 8 2018 2019; 57 211 2018; 170 2019; 6 2018; 1 2019; 13 2019 2018 2017 2019; 13 14 9 15 2019; 69 2019; 29 2019 2019 2020; 7 31 12 2019 2019 2019; 26 195 30 2018; 10 2019; 194 2018 2018 2019; 9 10 31 2019 2019 2019; 294 15 30 2019 2018 2019; 48 57 2 e_1_2_7_5_2 e_1_2_7_6_1 e_1_2_7_3_3 e_1_2_7_5_1 e_1_2_7_3_2 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_8_3 e_1_2_7_7_3 e_1_2_7_8_2 e_1_2_7_9_1 e_1_2_7_6_3 e_1_2_7_7_2 e_1_2_7_8_1 e_1_2_7_6_2 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_14_3 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_14_2 e_1_2_7_15_1 e_1_2_7_1_1 e_1_2_7_12_3 e_1_2_7_14_1 e_1_2_7_12_2 e_1_2_7_13_1 e_1_2_7_11_2 e_1_2_7_12_1 e_1_2_7_11_1 Zhang X. (e_1_2_7_3_4) 2019; 15 Duan X. (e_1_2_7_10_1) 2019; 9 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 Hao Y. (e_1_2_7_17_2) 2017; 4 |
| References_xml | – volume: 26 195 30 start-page: 16 63 2027 year: 2019 2019 2019 publication-title: Nano Today Biomaterials Chin. Chem. Lett. – volume: 7 31 12 start-page: 5019 3349 year: 2019 2019 2020 publication-title: J. Mater. Chem. B Chem. Mater. ACS Appl. Mater. Interfaces – volume: 57 211 start-page: 7066 68 year: 2018 2019 publication-title: Angew. Chem., Int. Ed. Engl. Biomaterials – volume: 13 start-page: 3083 year: 2019 publication-title: ACS Nano – volume: 294 15 30 start-page: 337 1923 485 year: 2019 2019 2019 publication-title: J. Controlled Release J. Biomed. Nanotechnol. Chin. Chem. Lett. – volume: 170 start-page: 147 year: 2018 publication-title: Biomaterials – volume: 194 start-page: 105 year: 2019 publication-title: Biomaterials – volume: 13 14 9 15 start-page: 8903 204 year: 2019 2018 2017 2019 publication-title: ACS Nano Small ACS Appl. Mater. Interfaces J. Biomed. Nanotechnol. – volume: 10 start-page: 3405 year: 2018 publication-title: ACS Appl. Mater. Interfaces – volume: 29 year: 2019 publication-title: Adv. Funct. Mater. – volume: 9 start-page: 757 year: 2019 publication-title: Mater. Express – volume: 9 10 31 start-page: 2053 year: 2018 2018 2019 publication-title: Nat. Commun. Nanoscale Adv. Mater. – volume: 5 start-page: 542 year: 2020 publication-title: Bioact. Mater. – volume: 6 year: 2019 publication-title: Adv. Sci. – volume: 8 start-page: 1558 year: 2018 publication-title: Theranostics – volume: 69 start-page: 363 year: 2019 publication-title: Ca‐Cancer J. Clin. – volume: 1 year: 2018 publication-title: Adv. Ther. – volume: 48 57 2 start-page: 771 year: 2019 2018 2019 publication-title: Chem. Soc. Rev. Angew. Chem., Int. Ed. Engl. Adv. Ther. – volume: 28 year: 2018 publication-title: Adv. Funct. Mater. – volume: 13 start-page: 7010 year: 2019 publication-title: ACS Nano – volume: 92 4 start-page: 219 1986 year: 2019 2017 publication-title: Acta Biomater. ACS Biomater. Sci. Eng. – volume: 6 year: 2016 publication-title: RSC Adv. – volume: 237 1 year: 2020 2020 publication-title: Biomaterials VIEW – ident: e_1_2_7_5_2 doi: 10.1002/viw2.6 – ident: e_1_2_7_6_3 doi: 10.1016/j.cclet.2019.04.052 – volume: 15 start-page: 204 year: 2019 ident: e_1_2_7_3_4 publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2019.2667 contributor: fullname: Zhang X. – ident: e_1_2_7_19_1 doi: 10.1021/acsami.7b17323 – ident: e_1_2_7_7_1 doi: 10.1016/j.jconrel.2018.12.042 – ident: e_1_2_7_14_1 doi: 10.1038/s41467-018-04318-1 – ident: e_1_2_7_5_1 doi: 10.1016/j.biomaterials.2020.119827 – ident: e_1_2_7_3_2 doi: 10.1002/smll.201803602 – ident: e_1_2_7_8_1 doi: 10.1039/C9TB00847K – ident: e_1_2_7_12_3 doi: 10.1002/adtp.201900059 – ident: e_1_2_7_17_1 doi: 10.1016/j.actbio.2019.05.008 – ident: e_1_2_7_6_2 doi: 10.1016/j.biomaterials.2018.12.032 – ident: e_1_2_7_12_1 doi: 10.1039/C8CS00304A – ident: e_1_2_7_7_3 doi: 10.1016/j.cclet.2018.06.009 – ident: e_1_2_7_21_1 doi: 10.1016/j.biomaterials.2018.04.015 – ident: e_1_2_7_14_3 doi: 10.1002/adma.201806803 – ident: e_1_2_7_22_1 doi: 10.1016/j.biomaterials.2018.12.021 – ident: e_1_2_7_24_1 doi: 10.1021/acsnano.9b02096 – ident: e_1_2_7_3_1 doi: 10.1021/acsnano.9b02477 – ident: e_1_2_7_12_2 doi: 10.1002/anie.201805138 – ident: e_1_2_7_15_1 doi: 10.1002/adfm.201805764 – ident: e_1_2_7_20_1 doi: 10.1002/adtp.201800008 – volume: 4 start-page: 1986 year: 2017 ident: e_1_2_7_17_2 publication-title: ACS Biomater. Sci. Eng. doi: 10.1021/acsbiomaterials.7b00523 contributor: fullname: Hao Y. – ident: e_1_2_7_2_1 doi: 10.1002/adfm.201808462 – ident: e_1_2_7_23_1 doi: 10.1002/adfm.201706310 – volume: 9 start-page: 757 year: 2019 ident: e_1_2_7_10_1 publication-title: Mater. Express doi: 10.1166/mex.2019.1552 contributor: fullname: Duan X. – ident: e_1_2_7_6_1 doi: 10.1016/j.nantod.2019.03.007 – ident: e_1_2_7_9_1 doi: 10.1021/acsnano.8b08346 – ident: e_1_2_7_3_3 doi: 10.1021/acsami.7b03604 – ident: e_1_2_7_11_1 doi: 10.1002/anie.201801984 – ident: e_1_2_7_13_1 doi: 10.1002/adfm.201806708 – ident: e_1_2_7_7_2 doi: 10.1166/jbn.2019.2821 – ident: e_1_2_7_1_1 doi: 10.3322/caac.21565 – ident: e_1_2_7_16_1 doi: 10.1016/j.bioactmat.2020.04.002 – ident: e_1_2_7_4_1 doi: 10.1002/advs.201901690 – ident: e_1_2_7_8_3 doi: 10.1021/acsami.0c00650 – ident: e_1_2_7_14_2 doi: 10.1039/C8NR07679K – ident: e_1_2_7_25_1 doi: 10.7150/thno.22989 – ident: e_1_2_7_11_2 doi: 10.1016/j.biomaterials.2019.04.029 – ident: e_1_2_7_8_2 doi: 10.1021/acs.chemmater.9b00439 – ident: e_1_2_7_18_1 doi: 10.1039/C5RA26563K |
| SSID | ssj0001537418 |
| Score | 2.585818 |
| Snippet | The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy and... Abstract The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy... Abstract The combination of chemotherapy and photodynamic therapy (PDT) has promising potential in the synergistic treatment of cancer. However, chemotherapy... |
| SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 2001853 |
| SubjectTerms | Cancer therapies chemophotodynamic therapy colon cancer Colorectal cancer Decomposition Efficiency Hypoxia Lasers Nanoparticles Particle size Photodynamic therapy platinum nanozymes Polyethylene glycol polymeric nanoparticles ROS‐responsive prodrugs Spectrum analysis |
| SummonAdditionalLinks | – databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hnrggyjNQkJGQgENUJ47j-AirVhUHWPUh9Rb5ySJRp1p2K9FTxS_gN_JLGNvZ1a5A6oXbauPNWjNjzzfxl28AXguuvbZclaK2osQUoEpMQx4_Mdtyw4V0iW3xqT06az6e8_ONVl-RE5blgbPh9i2WaMp0htWGNxqjhTcVtUJ6TD3UeZt234pvFFP5_WAWZVlWKo203lf2KqpzRwpRx9lWFkpi_f9CmH8TJTcBbMpAh_fh3ggdyfs85V2448ID2B0X53fydlSQfvcQfk6Hbz_SUQzB3RPL4pH9RuJTV3L8-eT3za_jkRx75cgUN9H58gtRwZJp5MaF5UX64TXehCCqJQdhlpgCJOoLDJezYTHY3MqenGZZAjJ4MsGNNJBJHDl_BGeHB6eTo3JstlCiQ-IJfBul9K3kzklptbaqqphXiAitV52vLdZFbYfoyStvlKaaGyeF4aaVQseHqY9hJwzBPQXi20aaTlgnrG2wHFKsUs5I2hntEP6oAt6sjN9fZk2NPqsn1310U792UwEfom_Wo6IWdvoCI6QfbdffFiEF7K08248LFP-i4XWHxRKlBbxaX8alFc9LVHDDMo1BsFhR2RXwJAfCeiaMVamdYQFiK0S2prp9JXydJfnu2EEAUVgBZQqmW0zQIzw5qSljz_6HLZ7D3XjnzEbcg53FfOleIKpa6JdpAf0BkgIh8w priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagvXBBLc_QgoyEBByiJnEcxydEV1tVHMpq20q9RX52K0GybHcrwQnxC_iN_BJmHG9gBYJblDgvjz3-PPPpG0JeCK69tlylorAihSVApbAMeThituKGC-kC2-KkOj4v313wixhwu460yrVPDI7adgZj5AeYIawB3WbZm_mnFKtGYXY1ltC4TbaLvMQ07fbh-GQy_RVl4QzlWdZqjVlxoOwNqnQjlajmbGM1CqL9f0OafxImfweyYSU62iF3I4Skb3ub75Jbrr1HduMkvaavopL06_vk26T78DmkZCh4UdgeRxYcxegrnb4__fH1-zSSZG8cnYAzXawuqWotnSBHrl19DDd-gYdQQLd03M4CY4CizkA3n3XLzvYl7elZL09AO09H4FBbOsKWiwfk_Gh8NjpOY9GFFAyDmfgKJfWt5M5JabW2Ks-ZV4AMrVe1Lyzsj6oaUJRX3iidaW6cFIabSgqNQdWHZKvtWveYUF-V0tTCOmFtCdsixXLljMxqox3AIJWQl-vOb-a9tkbTqygXDZqpGcyUkEO0zdAKNbHDiW5x2cS-ayxs5pWpDSsMLzX4FV7mmRXSA0jJnLcJ2V9btokTFV4xDKuEPB8uwxTDvIlqXbcKbQA05pmsE_KoHwjDlzCWh7KGCREbQ2TjUzevtFezIOONlQQAjSUkDYPpP13QAEw5LTLGnvz7N_bIHbyn5xvuk63lYuWeAm5a6mdxcvwE4TkbCQ priority: 102 providerName: ProQuest – databaseName: Wiley-Blackwell Titles (Open access) dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BuXBBlGegICMhAYeoSRzH8RFWrSoOsOpD6i3ys4sESbXdrQQnxC_gN_JLmHGyaSOQELcodpzI45n5xp58A_BSChOMEzqVhZMpugCdohsKeMVdJayQysdsiw_VwUn5_lScXvuLv-eHGDfcSDOivSYF1-Zi94o0VLtLotumnCB0OTfhFmKbmtZ1Uc6vdlkEJ3oWqjCH0XXK67LcMDdmxe50iIlnigT-f0OdfyZPXge10Svt34U7A5xkb3v5b8MN396D7UFhL9jrgVX6zX34Me8-f43HMwwtKobKQ0Yco51Ydvjx6Nf3n4dDwuylZ3M0rMv1GdOtY3PKl2vXX-KD33AQhkiX7bWLmD3AiHOgO190q8715e3ZcU9VwLrAZmhcWzajnssHcLK_dzw7SIcCDCkKiU7lK6LXd0p4r5Qzxuk850EjSnRB16FwGCtVNSKqoIPVJjPCeiWtsJWShjZYH8JW27X-MbBQlcrW0nnpXIkhkua59lZltTUeIZFO4NVm8pvznmej6RmVi4bE1IxiSuAdyWbsRfzY8Ua3PGuGuWscBvba1pYXVpQGbYwo88xJFRCwZD64BHY2km0GpcVXlKKoMYDKsgRejM2obnSGolvfrWMfBJB5puoEHvULYfwSzvNY4jABOVkik0-dtrSfFpHSm6oKIDJLII2L6R9T0CBkOSoyzp_8Z_-ncJtu9smIO7C1Wq79MwRVK_M86s1v67geKA priority: 102 providerName: Wiley-Blackwell |
| Title | Polymeric Nanoparticles with ROS‐Responsive Prodrug and Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon Cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadvs.202001853 https://www.ncbi.nlm.nih.gov/pubmed/33101874 https://www.proquest.com/docview/2452867500 https://www.proquest.com/docview/2454411098/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC7578901 https://doaj.org/article/d888ac8c32c54b6385410d79f2410efd |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFL00HYy-jHWf3rqgwWDbgxvbsiz7cQ0pZbDOpC30zeizKTR2yJLC9jT2C_Yb90t2JduhYYPB3owt27Lule650vERwBvOpJWaiZAnmocYAkSIYcjiEdUZU4wXxrMtTrOTi_TjJbvcAdb_C-NJ-0peH9Y388P6eua5lYu5GvU8sVH5aew02DGOjQYw4JTeSdHbX4OpU2TpBRqjZCT0rRPmduwhDE57cJ_S2O9FtxWLvGT_33Dmn3TJuzDWx6Hjh_CgA5DkQ1vRfdgx9SPY77roF_Ku05F-_xh-lM3NV78gQ3AMxeS4-zbi5l7J9PPZr-8_px1F9taQEofS5fqKiFqT0jHk6vXc3_gNH0IQ25JJPfN8AeJUBprFrFk1ut3Qnpy34gSksWSMw2lNxq7k8glcHE_Oxydht-VCiGZx6_CZE9TXBTOmKLSUWsQxtQJxobYit4nG7CjLEUNZYZWQkWTKFFwxlRVcuinVp7BbN7V5DsRmaaFyrg3XOsWkSNBYGFVEuZIGQZAI4G3f-NWiVdaoWg3lpHIWqzYWC-DI2WZTyili-xPN8qrq2q7SmMoLlSuaKJZKHFVYGkeaFxYhSmSsDuCgt2zVdVN8RcqSHFOmKArg9eYydjC3aiJq06x9GYSMcVTkATxrHWFTk96RAuBbLrJV1e0r6NNexLvz4QBC70z_aIIKQcpZElH64r_f9BL23ONaIuIB7K6Wa_MKAdVKDmGQpOUQ7h1NTsvp0E9LDH2n-g1DTCYP |
| link.rule.ids | 230,315,733,786,790,870,891,2115,11589,21416,27955,27956,33777,33778,43838,46085,46509,50847,50956,53825,53827,74657 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEB5BeoALojwNBRYJCThY9Wv9OCEapQpQQpSmUm_WPhsksEOaVIIT4hfwG_klzKw3gQgEN8tev3Z2Z7-d-fQNwJOCSys1F2GR6CLEJUCEuAxZPEp1zhUvKuPYFqN8eJK9PuWnPuB27mmVa5_oHLVuFcXI9ylDWCK6jaIX808hVY2i7KovoXEZdkhys-zBzsFgNJ78irLwlORZ1mqNUbIv9AWpdBOVqOTp1mrkRPv_hjT_JEz-DmTdSnR4Ha55CMledjbfhUumuQG7fpKes2deSfr5Tfg2bj98dikZhl4Ut8eeBcco-som745_fP0-8STZC8PG6EwXqzMmGs3GxJFrVh_djV_wIQzRLRs0M8cYYKQz0M5n7bLVXUl7Nu3kCVhrWR8dasP61HJxC04OB9P-MPRFF0I0DGXic5LU1xU3pqq0lFrEcWoFIkNtRWkTjfujvEQUZYVVQkaSK1MViqu8KiQFVW9Dr2kbcxeYzbNKlYU2hdYZbotEGgujqqhU0iAMEgE8XXd-Pe-0NepORTmpyUz1xkwBHJBtNq1IE9udaBdnte-7WuNmXqhSpYnimUS_wrM40kVlEaRExuoA9taWrf1ExVdshlUAjzeXcYpR3kQ0pl25Ngga46gqA7jTDYTNl6Rp7MoaBlBsDZGtT92-0ryfORlvqiSAaCyA0A2m_3RBjTDlOInS9N6_f-MRXBlO3x7VR69Gb-7DVbq_4x7uQW-5WJkHiKGW8qGfKD8Ba_Ud_w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLZgkxAviHFbYICRkICHqEkcx_ETYqXVuKhE3SbtLfJ1RYKkdO0keEL7BfuN_BKOHTdQgeCtapw28fE5_o7Pp-8g9JRRaaWmImaZZjFsASKGbcjCJ6ILqijjxrMtJsXBcf72hJ4E_tNZoFWuY6IP1LpV7ox84CqEJaDbJBnYQIuoXo9fzr_EroOUq7SGdhpX0TbLCwqJ2Pb-aFJNf524UOKkWtbKjUk2EPrcKXY7WlFJycbO5AX8_4Y6_yRP_g5q_a40voluBDiJX3X230FXTHML7QSHPcPPg6r0i9voomo_ffXlGQwRFVLlwIjD7iQWTz8c_vh-OQ2E2XODKwisi9UpFo3GlePLNavP_sZv8CMYkC4eNTPPHsBOc6Cdz9plq7v29viokyrArcVDCK4NHrqRizvoeDw6Gh7EoQFDDEZyVfnCyetrTo3hXEupRZoSKwAlaitKm2nIlYoSEJUVVgmZSKoMZ4qqgjPpDljvoq2mbcwuwrbIuSqZNkzrHFIkQVJhFE9KJQ1AIhGhZ-vJr-edzkbdKSpntTNT3ZspQvvONv0op4_tv2gXp3WYu1pDYi9UqUimaC4hxtA8TTTjFgBLYqyO0N7asnVwWviLfolF6El_GdzN1VBEY9qVHwMAMk14GaF73ULon4SQ1Lc4jBDbWCIbj7p5pfk485LerqsAILMIxX4x_WcKaoAsh1lCyP1_v8ZjdA18pH7_ZvLuAbrubu9oiHtoa7lYmYcAp5byUfCTn7XlIjM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymeric+Nanoparticles+with+ROS%E2%80%90Responsive+Prodrug+and+Platinum+Nanozyme+for+Enhanced+Chemophotodynamic+Therapy+of+Colon+Cancer&rft.jtitle=Advanced+science&rft.au=Hao%2C+Ying&rft.au=Chen%2C+Yuwen&rft.au=He%2C+Xinlong&rft.au=Yu%2C+Yongyang&rft.date=2020-10-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=2198-3844&rft.volume=7&rft.issue=20&rft_id=info:doi/10.1002%2Fadvs.202001853&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2198-3844&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2198-3844&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2198-3844&client=summon |